semaglutide compounding fda news issues warning about some compounded versions of for diabetes, weight loss π¨ FDA Moves to Permanently
Description
In January 2025, Metsera, a New York-based obesity healthcare company, announced positive topline results from its Phase IIa clinical trial for MET-097i, a glucagon-like peptide-1 receptor agonist (GLP-1RA)
Well help you choose the most appropriate option based on your profile
The decision to continue or stop treatment should be made collaboratively, weighing the metabolic benefits against any potential risks to psychological wellbeing
How your diet can affect GLP-1 production
[DOI] [PMC free article] [PubMed] [Google Scholar] 96.Harrison SA, Bedossa P, Guy CD, et al
